

Amanda J Fosang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5040171/publications.pdf>

Version: 2024-02-01

68
papers

5,865
citations

94433

37
h-index

102487

66
g-index

87
all docs

87
docs citations

87
times ranked

5365
citing authors

#	ARTICLE	IF	CITATIONS
1	Metalloprotease inhibitor TIMP proteins control FGF-2 bioavailability and regulate skeletal growth. <i>Journal of Cell Biology</i> , 2019, 218, 3134-3152.	5.2	16
2	Adamts5 ^{-/-} Mice Exhibit Altered Aggrecan Proteolytic Profiles That Correlate With Ascending Aortic Anomalies. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 2067-2081.	2.4	32
3	ADAMTS-9 in Mouse Cartilage Has Aggrecanase Activity That Is Distinct from ADAMTS-4 and ADAMTS-5. <i>International Journal of Molecular Sciences</i> , 2019, 20, 573.	4.1	12
4	Cartilage MicroRNA Dysregulation During the Onset and Progression of Mouse Osteoarthritis Is Independent of Aggrecanolysis and Overlaps With Candidates From End-Stage Human Disease. <i>Arthritis and Rheumatology</i> , 2018, 70, 383-395.	5.6	21
5	Glucocorticoids influence versican and chondroitin sulphate proteoglycan levels in the fetal sheep lung. <i>Respiratory Research</i> , 2018, 19, 155.	3.6	5
6	An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2. <i>JCI Insight</i> , 2018, 3, .	5.0	72
7	Proteoglycan and Collagen Degradation in Osteoarthritis. , 2017, , 41-61.		6
8	Brief Report: JNK ϵ 2 Controls Aggrecan Degradation in Murine Articular Cartilage and the Development of Experimental Osteoarthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1165-1171.	5.6	49
9	Wide bandwidth nanomechanical assessment of murine cartilage reveals protection of aggrecan knock-in mice from joint-overuse. <i>Journal of Biomechanics</i> , 2016, 49, 1634-1640.	2.1	20
10	Novel Elements of the Chondrocyte Stress Response Identified Using an in Vitro Model of Mouse Cartilage Degradation. <i>Journal of Proteome Research</i> , 2016, 15, 1033-1050.	3.7	27
11	A Disintegrin and Metalloproteinase with Thrombospondin Motifs-5 (ADAMTS-5) Forms Catalytically Active Oligomers. <i>Journal of Biological Chemistry</i> , 2016, 291, 3197-3208.	3.4	12
12	Transparency Is the Key to Quality. <i>Journal of Biological Chemistry</i> , 2015, 290, 29692-29694.	3.4	84
13	Bioactivity in an Aggrecan 32 μ m Fragment Is Mediated via Toll-like Receptor 2. <i>Arthritis and Rheumatology</i> , 2015, 67, 1240-1249.	5.6	76
14	ADAMTS-5 takes centre stage in new developments for aggrecanase inhibitors. <i>Osteoarthritis and Cartilage</i> , 2015, 23, 1231-1232.	1.3	7
15	High-bandwidth AFM-based rheology is a sensitive indicator of early cartilage aggrecan degradation relevant to mouse models of osteoarthritis. <i>Journal of Biomechanics</i> , 2015, 48, 162-165.	2.1	40
16	Abundant LacZ activity in the absence of Cre expression in the normal and inflamed synovium of adult Col2a1-Cre; ROSA26RLacZ reporter mice. <i>Osteoarthritis and Cartilage</i> , 2013, 21, 401-404.	1.3	14
17	Mast Cell-Restricted, Tetramer-Forming Trypsases Induce Aggrecanolysis in Articular Cartilage by Activating Matrix Metalloproteinase-3 and -13 Zymogens. <i>Journal of Immunology</i> , 2013, 191, 1404-1412.	0.8	32
18	Transcriptomics of Wild-Type Mice and Mice Lacking ADAMTS ϵ 5 Activity Identifies Genes Involved in Osteoarthritis Initiation and Cartilage Destruction. <i>Arthritis and Rheumatism</i> , 2013, 65, 1547-1560.	6.7	56

#	ARTICLE	IF	CITATIONS
19	Evidence for lysosomal exocytosis and release of aggrecan-degrading hydrolases from hypertrophic chondrocytes, <i>in vitro</i> and <i>in vivo</i> . <i>Biology Open</i> , 2012, 1, 318-328.	1.2	11
20	Aggrecanase cleavage in juvenile idiopathic arthritis patients is minimally detected in the aggrecan interglobular domain but robust at the aggrecan C-terminus. <i>Arthritis and Rheumatism</i> , 2012, 64, 4151-4161.	6.7	12
21	Proteoglycan degradation by the ADAMTS family of proteinases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 1616-1629.	3.8	148
22	Matrilin-4 is processed by ADAMTS-5 in late Golgi vesicles present in growth plate chondrocytes of defined differentiation state. <i>Matrix Biology</i> , 2011, 30, 275-280.	3.6	10
23	Investigating ADAMTS-mediated aggrecanolytic activity in mouse cartilage. <i>Nature Protocols</i> , 2011, 6, 388-404.	12.0	63
24	Emerging Frontiers in cartilage and chondrocyte biology. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 751-766.	3.3	64
25	Is Cartilage Matrix Breakdown an Appropriate Therapeutic Target in Osteoarthritis? Insights from Studies of Aggrecan and Collagen Proteolysis?. <i>Current Drug Targets</i> , 2010, 11, 561-575.	2.1	65
26	Identifying the human aggrecanase. <i>Osteoarthritis and Cartilage</i> , 2010, 18, 1109-1116.	1.3	51
27	Cytokine-induced increases in ADAMTS-4 messenger RNA expression do not lead to increased aggrecanase activity in ADAMTS-5-deficient mice. <i>Arthritis and Rheumatism</i> , 2010, 62, 3365-3373.	6.7	42
28	Internalization of Aggrecan G1 Domain Neopeptide ITEGE in Chondrocytes Requires CD44. <i>Journal of Biological Chemistry</i> , 2010, 285, 36216-36224.	3.4	24
29	Neopeptide Antibodies Against MMP-Cleaved and Aggrecanase-Cleaved Aggrecan. <i>Methods in Molecular Biology</i> , 2010, 622, 305-340.	0.9	21
30	Employing molecular genetics of chondrodysplasias to inform the study of osteoarthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 325-334.	6.7	43
31	Keratan sulphate in the interglobular domain has a microstructure that is distinct from keratan sulphate elsewhere on pig aggrecan. <i>Matrix Biology</i> , 2009, 28, 53-61.	3.6	12
32	Hyaluronan synthesis and degradation in cartilage and bone. <i>Cellular and Molecular Life Sciences</i> , 2008, 65, 395-413.	5.4	164
33	Evidence of a novel aggrecan-degrading activity in cartilage: Studies of mice deficient in both ADAMTS-4 and ADAMTS-5. <i>Arthritis and Rheumatism</i> , 2008, 58, 1664-1673.	6.7	57
34	Proteomic characterization of mouse cartilage degradation <i>in vitro</i> . <i>Arthritis and Rheumatism</i> , 2008, 58, 3120-3131.	6.7	58
35	Drug Insight: aggrecanases as therapeutic targets for osteoarthritis. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 420-427.	3.2	89
36	Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. <i>Arthritis Research and Therapy</i> , 2008, 10, R63.	3.5	161

#	ARTICLE	IF	CITATIONS
37	Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. <i>Journal of Clinical Investigation</i> , 2008, 118, 3812-3812.	8.2	4
38	ADAMTS-5 Deficiency Does Not Block Aggrecanolytic Activity at Preferred Cleavage Sites in the Chondroitin Sulfate-rich Region of Aggrecan. <i>Journal of Biological Chemistry</i> , 2007, 282, 8632-8640.	3.4	54
39	Distinguishing Aggrecan Loss from Aggrecan Proteolysis in ADAMTS-4 and ADAMTS-5 Single and Double Deficient Mice. <i>Journal of Biological Chemistry</i> , 2007, 282, 37420-37428.	3.4	28
40	Changes in versican and chondroitin sulfate proteoglycans during structural development of the lung. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2007, 293, R784-R792.	1.8	26
41	Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. <i>Arthritis and Rheumatism</i> , 2007, 56, 1549-1558.	6.7	62
42	Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. <i>Journal of Clinical Investigation</i> , 2007, 117, 1627-1636.	8.2	171
43	The accumulation of intracellular ITEGE and DIPEN neoepitopes in bovine articular chondrocytes is mediated by CD44 internalization of hyaluronan. <i>Arthritis and Rheumatism</i> , 2006, 54, 443-454.	6.7	27
44	ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. <i>Nature</i> , 2005, 434, 648-652.	27.8	826
45	Reduction of arthritis severity in protease-activated receptor-deficient mice. <i>Arthritis and Rheumatism</i> , 2005, 52, 1325-1332.	6.7	54
46	ADAMTS-1-Knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo. <i>Arthritis and Rheumatism</i> , 2005, 52, 1461-1472.	6.7	100
47	Matrix Metalloproteinases Are Not Essential for Aggrecan Turnover during Normal Skeletal Growth and Development. <i>Molecular and Cellular Biology</i> , 2005, 25, 3388-3399.	2.3	48
48	N-Linked Keratan Sulfate in the Aggrecan Interglobular Domain Potentiates Aggrecanase Activity. <i>Journal of Biological Chemistry</i> , 2005, 280, 23615-23621.	3.4	28
49	The role of hepatocyte growth factor in the humoral regulation of inguinal hernia closure. <i>Journal of Pediatric Surgery</i> , 2005, 40, 1865-1868.	1.6	11
50	Cortisol enhances structural maturation of the hypoplastic fetal lung in sheep. <i>Journal of Physiology</i> , 2004, 554, 505-517.	2.9	25
51	Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. <i>Development (Cambridge)</i> , 2004, 131, 5883-5895.	2.5	521
52	ADAMTS4 Cleaves at the Aggrecanase Site (Glu373-Ala374) and Secondarily at the Matrix Metalloproteinase Site (Asn341-Phe342) in the Aggrecan Interglobular Domain. <i>Journal of Biological Chemistry</i> , 2002, 277, 16059-16066.	3.4	81
53	The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases. <i>Biochemical Journal</i> , 2002, 364, 181-190.	3.7	107
54	Matrix metalloproteinases are active following guanidine hydrochloride extraction of cartilage: generation of DIPEN neoepitope during dialysis. <i>Matrix Biology</i> , 2002, 21, 425-428.	3.6	13

#	ARTICLE	IF	CITATIONS
55	To clot or not. Nature, 2001, 413, 475-476.	27.8	24
56	Immunolocalization of Matrix Metalloproteinases in Partial-Thickness Defects in Pig Articular Cartilage. Journal of Bone and Joint Surgery - Series A, 2001, 83, 826-838.	3.0	58
57	Generation and Novel Distribution of Matrix Metalloproteinase-derived Aggrecan Fragments in Porcine Cartilage Explants. Journal of Biological Chemistry, 2000, 275, 33027-33037.	3.4	68
58	Mutations in the Interglobular Domain of Aggrecan Alter Matrix Metalloproteinase and Aggrecanase Cleavage Patterns. Journal of Biological Chemistry, 2000, 275, 33038-33045.	3.4	47
59	Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Letters, 2000, 478, 52-56.	2.8	110
60	Recombinant Human Aggrecan G1-G2 Exhibits Native Binding Properties and Substrate Specificity for Matrix Metalloproteinases and Aggrecanase. Journal of Biological Chemistry, 1999, 274, 32387-32395.	3.4	35
61	Aggrecanase and cartilage proteoglycan degradation. , 1999, , 117-143.		1
62	Membrane-type 1 MMP (MMP-14) cleaves at three sites in the aggrecan interglobular domain. FEBS Letters, 1998, 430, 186-190.	2.8	52
63	Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Letters, 1996, 380, 17-20.	2.8	326
64	Gelatinase A possesses a Î²-secretase-like activity in cleaving the amyloid protein precursor of Alzheimer's disease. FEBS Letters, 1995, 377, 267-270.	2.8	43
65	The sulphation pattern in chondroitin sulphate chains investigated by chondroitinase ABC and ACII digestion and reactivity with monoclonal antibodies. Carbohydrate Research, 1994, 255, 241-254.	2.3	26
66	Proteoglycans: many forms and many functions. FASEB Journal, 1992, 6, 861-870.	0.5	1,101
67	Effect of Interleukin-1 and Insulin Like Growth Factor-1 on the Release of Proteoglycan Components and Hyaluronan from Pig Articular Cartilage in Explant Culture. Matrix Biology, 1991, 11, 17-24.	1.7	99
68	Connective Tissue Remodelling in the Ovine Cervix During Pregnancy and at Term. Connective Tissue Research, 1988, 17, 277-285.	2.3	13